Astellas Pharma (STU:YPH) Net Change in Cash : €-905 Mil (TTM As of Mar. 2025)

View and export this data going back to . Start your Free Trial

What is Astellas Pharma Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Astellas Pharma's Net Change in Cash for the three months ended in Mar. 2025 was €53 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2025 was €-905 Mil.

Astellas Pharma Net Change in Cash Historical Data

The historical data trend for Astellas Pharma's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma Net Change in Cash Chart

Astellas Pharma Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Net Change in Cash

Get a 7-Day Free Trial

59.79

-77.66

425.23

-252.72

-914.18

Astellas Pharma Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Net Change in Cash	Get a 7-Day Free Trial															501.74	-192.79	-62.61	-702.38	52.79

Astellas Pharma Net Change in Cash Calculation

Astellas Pharma's Net Change in Cash for the fiscal year that ended in Mar. 2025 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	1207.074	+	-554.903	+	-1621.953	+	55.603
	=	-914

Astellas Pharma's Net Change in Cash for the quarter that ended in Mar. 2025

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= 627.237 + -18.4 + -563.548 + 7.503

= 53

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-905 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Astellas Pharma Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Astellas Pharma's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Astellas Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (STU:YPH) » Definitions » Net Change in Cash

Comparable Companies

TSE:4578 TSE:4151 TSE:4528 TSE:4536 TSE:4552 TSE:4882 TSE:4568 LLY JNJ ABBV OCSE:NOVO B XSWX:ROG XSWX:NOVN LSE:AZN MRK AMGN PFE GILD XPAR:SAN BMY

Traded in Other Exchanges

ALPMY:USA ALPMF:USA 4503:Japan

Address

2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411

Website

http://www.astellas.com

Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.

Astellas Pharma Headlines

No Headlines